The Australian Immunisation Handbook 10th Edition 2013

inactivated poliomyelitis vaccine (IPV),
68–69, 118, 138, 156, 194, 339, 341. see also
poliomyelitis
Indigenous community workers, vaccination
recommendations, 172
Indigenous persons. see Aboriginal and Torres
Strait Islander people
indurated lesions, 352
Infanrix hexa, 51, 67, 183, 193, 195, 211, 305,
339–340, 342, 399
dosage and administration, 214, 217
transport, storage and handling, 185, 194,
217, 307, 341, 401
vaccination schedule, 214
vaccine components, 470–472
variations from product information, 188,
190, 197, 230, 314, 316, 343, 405, 407
Infanrix IPV, 184, 305, 340, 342, 399
vaccine components, 469–472
variations from product information, 188,
190, 314, 316, 343–344, 406, 407
infants
cholera, 186
diphtheria, 186
Haemophilus influenzae type b (Hib), 195
hepatitis B, 212, 214–215, 218–220, 219
influenza, 251
injection sites, 73
measles, post-exposure prophylaxis, 281
measles, vaccination, 271–272
meningococcal disease, 290
multiple vaccine injections, 83
mumps, 299
pertussis, 307–308, 309–310
poliomyelitis, 342
positioning for vaccination, 75–76, 77
rabies, 356–357
rotavirus, 377–378, 380–381
rubella, 388
tetanus, 401
tuberculosis, 410, 412, 414
vaccination recommendations for parents,
grandparents and carers, 36, 309
yellow fever, 443, 445
zoster immunoglobulin, 435–436
influenza
adverse events following immunisation
(AEFI), 257–258
changes in the 10th edition of the
handbook, 13
clinical features, 243–244
co-administration with other vaccines, 251
contraindications to vaccination, 256
dosage and administration, 250–251
and egg allergies, 256–257
epidemiology, 244–246
higher risk groups, 252–256
510 The Australian Immunisation Handbook 10th edition
and HIV-infected persons, 160
and immunocompromised persons, 145
and Indigenous persons, 108, 109–110, 254
national notification and hospitalisation
rates, 245
and persons with asplenia, 162, 163–164
precautions, 256–257
pregnancy and breastfeeding, 135, 256
and preterm infants, 144
public health management, 258
recommendations, 251–256
route of vaccine administration, 68–69
transport, storage and handling, 250
and travellers, 118
vaccination and egg allergies, 132
vaccines, 246–250
variations from product information, 258
virology, 243
influenza pandemic, 245–246
Influvac, 247
vaccine components, 470–472
Influvac Junior, 247
injecting drug users. see drugs, persons who
inject
injection of vaccines, 66–67
injection site abscess
and Q fever vaccination, 351
and tuberculosis vaccination, 414
injection site nodules, 91
injection site reactions, 63, 74
and human papillomavirus (HPV)
vaccination, 241
and Japanese encephalitis vaccination,
265–266
and pneumococcal vaccination, 323
and tetanus vaccination, 404–405
and varicella vaccination, 433
and zoster vaccination, 448, 451, 452, 454
injection sites
adolescents, 74
adults, 74
breast cancer or lymphoedema patients, 74
children, 73–74
children in spica casts, 74
children with congenital limb
malformation, 74
identification of, 79–82
infants, 73
multiple injections, 83–84
injection techniques
intradermal injection, 72
intramuscular injection, 71–73
subcutaneous injection, 72
inmates of correctional facilities. see
correctional facility inmates
Intanza 9 mg, 68, 72, 248, 249
Intanza 15 mg, 68, 72, 248, 249